Get started
Author

Hun Sheng Chuah

Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab
2025 · Shaji Kumar, María-Victoria Mateos, et al. · New England Journal of Medicine · 48
Transform-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis
2023 · Naveen Pemmaraju, Adam J Mead, et al. · Blood · 43
PDF
Blood use in patients receiving intensive chemotherapy for acute leukemia or hematopoietic stem cell transplantation: the impact of a health system–wide patient blood management program
2017 · Michael F. Leahy, Kevin M. Trentino, et al. · Transfusion · 33
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial
2025 · Lorenzo Falchi, Marcel Nijland, et al. · The Lancet · 31
“Immuno‐flowFISH” for the Assessment of Cytogenetic Abnormalities in Chronic Lymphocytic Leukemia
2019 · Henry Y.L. Hui, Kathryn M. Clarke, et al. · Cytometry Part A · 29
Imaging flow cytometry to assess chromosomal abnormalities in chronic lymphocytic leukaemia
2017 · Henry Hui, Kathryn A. Fuller, et al. · Methods · 29
Platelets in myeloproliferative neoplasms have a distinct transcript signature in the presence of marrow fibrosis
2019 · Belinda B. Guo, Matthew D. Linden, et al. · British Journal of Haematology · 24
PDF
Megakaryocytes in Myeloproliferative Neoplasms Have Unique Somatic Mutations
2017 · Belinda B. Guo, Richard J. Allcock, et al. · American Journal Of Pathology · 19
PDF
Megakaryocyte emperipolesis in myeloproliferative neoplasms: Are neutrophils friends or foes?
2025 · Ryan J Collinson, Matthew D Linden, et al. · Journal of Leukocyte Biology · 10
PDF
Optimal enoxaparin dosing strategies for venous thromboembolism prophylaxis and treatment of high body weight patients
2021 · Annalise M. Martin, Paola Polistena, et al. · Thrombosis Research · 10
Efficacy and safety of talquetamab + teclistamab in patients with Relapsed/Refractory multiple myeloma and extramedullary disease: Updated Phase 2 results from the redirectt-1 study with extended follow-up
2025 · Saad Usmani, Shaji Kumar, et al. · Blood · 6
PDF
Imaging flow cytometric detection of del( 17p ) in bone marrow and circulating plasma cells in multiple myeloma
2024 · Thomas I. Mincherton, Stephanie J. Lam, et al. · International Journal of Laboratory Hematology · 6
Phase 1b study of ABBV-744, a novel, selective BET inhibitor, as monotherapy for patients with myelofibrosis
2026 · John Mascarenhas, Laura Fogliatto, et al. · Blood Advances · 5
PDF
PlateletSeq: A novel method for discovery of blood-based biomarkers
2023 · Ryan J. Collinson, Darren Boey, et al. · Methods · 5
Phase 3, Randomized, Open-Label Study of Epcoritamab Plus Lenalidomide Compared with Rituximab Plus Gemcitabine and Oxaliplatin in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
2024 · Muhit Ozcan, Won Seog Kim, et al. · Blood · 4
PDF
Transcription factor 3 is dysregulated in megakaryocytes in myelofibrosis
2024 · Ryan J Collinson, Lynne Wilson, et al. · Platelets · 4
Jumping translocation involving chromosome 13q in a patient with Crohn's Disease and inv(16)(p13.1q22)/CBFB-MYH11 acute myeloid leukemia
2022 · Sarah Clarke, Rebecca de Kraa, et al. · Cancer Genetics · 3
Angiotensin‐converting enzyme inhibitor and visceral angio‐oedema
2012 · Hun Sheng Chuah, Daniel O'Donnell · Emergency Medicine Australasia · 3
Updated Interim Results of Sonrotoclax + Dexamethasone in Patients With t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (R/R MM): An All-Oral Treatment
2025 · Binod Dhakal, Malin Hultcrantz, et al. · Clinical Lymphoma Myeloma & Leukemia · 2
First results from the Phase 1 study of APL-4098, an oral potent GCN2 inhibitor for the treatment of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) and Myelodysplastic Syndromes (MDS)/AML
2025 · Shaun Fleming, Shuhying Tan, et al. · Blood · 1
PDF
Strike three for the 8p11 – an illustrative case of variable clinical presentations in a patient with myeloid/lymphoid neoplasms with FGFR1 rearrangement
2024 · Caitlin Rice, Paul Cannell, et al. · Pathology · 1
PDF
“Double Hit” Myeloma: Detection By FISH and Flow Cytometry in Circulating Myeloma Plasma Cells
2023 · Wendy N. Erber, Thomas Mincherton, et al. · Blood · 1
P1038: Tl-895, a First-in-class, Covalent Bruton Tyrosine Kinase Inhibitor (btki) for the Treatment of Myelofibrosis (mf) Patients (pts) With Severe Thrombocytopenia (platelets (plts) <50 K/ul)
2023 · Michael Loschi, Laszlo Rejto, et al. · HemaSphere · 1
Navitoclax monotherapy or in combination with ruxolitinib in patients with JAK2 inhibitor-treated myelofibrosis: results from the phase 2 REFINE and phase 3 TRANSFORM-2 studies
2026 · Raajit K. Rampal, Claire N. Harrison, et al. · Leukemia & lymphoma/Leukemia and lymphoma
PDF
Safety, tolerability, and efficacy of mesutoclax (ICP-248) in combination with azacitidine in patients with myeloid malignancies.
2026 · Huafeng Wang, Qian Jiang, et al. · Journal of Clinical Oncology
Works count: 41
Citation count: 318
H-index: 10
I10-index: 10
Year
Topic
Type